

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/808,225	03/14/2001	Walter Schubert	HSS-016XX	2805
207	7590 10/01/2003		EXAMI	NER
WEINGARTEN, SCHURGIN, GAGNEBIN & LEBOVICI LLP			SHAHNAN SHAH, KHATOL S	
TEN POST (BOSTON, N	OFFICE SQUARE MA 02109		ART UNIT PAPER NUMBER 1645	
			DATE MAILED: 10/01/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

		A liastion No	Applicant/a)		
•		Application No.	Applicant(s)		
		09/808,225	SCHUBERT, WALTER		
	Office Action Summary	Examiner	Art Unit		
		Khatol S Shahnan-Shah	1645		
<i>۱۱</i> Period for R	he MAILING DATE of this communication app eply	ears on the cover sheet with the c	orrespondence address		
THE MAI - Extension after SIX (- If the peric - If NO peric - Failure to - Any reply	TENED STATUTORY PERIOD FOR REPLY LING DATE OF THIS COMMUNICATION. sof time may be available under the provisions of 37 CFR 1.13 6) MONTHS from the mailing date of this communication. od for reply specified above is less than thirty (30) days, a reply do for reply is specified above, the maximum statutory period we reply within the set or extended period for reply will, by statute, received by the Office later than three months after the mailing lent term adjustment. See 37 CFR 1.704(b).	obsides. In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).		
1)⊠ R	esponsive to communication(s) filed on 14 M	<u>farch 2001</u> .			
2a)	nis action is FINAL . 2b)⊠ Thi	s action is non-final.			
cl	nce this application is in condition for allowa osed in accordance with the practice under <i>l</i>				
Disposition					
•	nim(s) <u>1-12</u> is/are pending in the application				
	Of the above claim(s) is/are withdraw	vn from consideration.			
<u> </u>	Claim(s) is/are allowed.				
·	Claim(s) <u>1-12</u> is/are rejected.				
- A	nim(s) is/are objected to.				
	nim(s) are subject to restriction and/or	r election requirement.			
Application					
•	specification is objected to by the Examiner drawing(s) filed on is/are: a) accep		minor		
-	pplicant may not request that any objection to the				
	proposed drawing correction filed on	= , ,	· ' '		
	approved, corrected drawings are required in rep		vod by the Examiner.		
	oath or declaration is objected to by the Ex				
•	er 35 U.S.C. §§ 119 and 120				
<u> </u>	knowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d) or (f).		
•	NI b)⊠ Some * c)□ None of:	, p	, (-, -, (,)		
· _	✓ Certified copies of the priority documents	s have been received.			
_	2. Certified copies of the priority documents have been received in Application No				
	Copies of the certified copies of the prior application from the International Bur the attached detailed Office action for a list of the action fo	ity documents have been receive eau (PCT Rule 17.2(a)).	ed in this National Stage		
	nowledgment is made of a claim for domestic	•			
_a) [The translation of the foreign language pronowledgment is made of a claim for domesti	visional application has been rec	eived.		
Attachment(s)		,,			
1) Notice of Notice of	References Cited (PTO-892) Draftsperson's Patent Drawing Review (PTO-948) on Disclosure Statement(s) (PTO-1449) Paper No(s) <u>4</u> .	5) 🔲 Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)		
S. Patent and Tradem	ark Office				

Art Unit: 1645

Detailed Action

- Applicant's Information disclosure statement, received 06/14/2001, paper # 4 is acknowledged.
- 2. Applicant's preliminary amendment A, received 3/14/2001, paper # 6 is acknowledged. Applicant amended claims 3, 4, 5, and 7. New claims 10-12 were added.
- 3. Claims 1-12 are pending and under consideration.

Abstract

4. The abstract of the disclosure is objected to because it exceeds one paragraph. Applicant is reminded of the proper language and format for an abstract of the disclosure. The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words. It is important that the abstract not exceed 150 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details. The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc. Correction is required. See MPEP § 608.01(b).

Specification

5. The disclosure is objected to because of the following informalities:

Page 1 of the specification has a sticker with an express mail number. Appropriate correction is required.

Art Unit: 1645

Priority

6. An application in which the benefits of an earlier application are desired must contain a specific reference to the prior application(s) in the first sentence of the specification (37 CFR 1.78).

Complete priority statement is missing from specification:

A statement reading, "This application claims priority to a German application No. 100 14 708.9, filed on 3/24/2000" should be entered following the title of the invention or as the first sentence of the specification.

Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) a translation of the foreign application should be submitted under 37 CFR 1.55 in reply to this action. A claim for priority under 35 U.S.C. 119 (a) (d) (e) cannot be based on said application, until proper corrections are made.

Double Patenting

7. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ormum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

8. Claims 1-12 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 6,150,173. Although the

Art Unit: 1645

conflicting claims are not identical, they are not patentably distinct from each other because the claims of current application and Patent No. 6,150,173 are both drawn to an automated method for determining or identifying cell-specific target structures or molecular classes.

9. Claims 1-12 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-15 of copending Application No. 09/808,224. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of both applications are drawn to an automated method for determining or identifying cell-specific target structures or molecular classes.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 112

10. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

11. Claims 1-12 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 recites the limitation "the surface" in line 4. There is insufficient antecedent basis for this limitation in the claim.

It is not clear what constitutes the metes and bounds of Yn (n= 2, 3,., N) and Xn (n= 2, 3,., N) in claims 4, 9, 10 and 12.

It is not clear what applicant indents in recitation of "in particular a protein separation process" in claim 5. The process is not defined by the claim, the specification does not provide a

Art Unit: 1645

definition, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention.

It is not clear what applicant indents in recitation of "by means of a molecule or molecular complex separation process "in claim 5. The process is not defined by the claim, the specification does not provide a definition, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention.

Conclusion

- 12. No claims are allowed.
- Any inquiry concerning this communication or earlier communications from the examiner should be directed to Khatol Shahnan-Shah whose telephone number is (703) 308-8896. The examiner can normally be reached from 7:30 AM 4 PM on Monday through Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette F Smith, can be reached on (703) 308-3909. The fax phone number for the organization where this application or proceeding is assigned to is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Khatol Shahnan-Shah, BS, Pharm, MS

Biotechnology Patent Examiner

Art Unit 1645

September 29, 2003

RODNEY P SWARTZ, PH.D